FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D



L540cy
Mean tumor chart
Untreated
SGN-CD30C 0.1 mg/kg
BV 0.3 mg/kg
SGN-CD30C 0.1 mg/kg + BV 0.3 mg/kg
Mean Tumor Volume (mm3)
1000
800
600
400
200
0
0
20
40
60
80
Days

FIG. 1E



L540cy
Survival Based on Time to Tumor Quadrupling
Untreated
SGN-CD30C 0.1 mg/kg
BV 0.3 mg/kg
SGN-CD30C 0.1 mg/kg + BV 0.3 mg/kg combo
Time to Tumor Quadrupling (wks)
6
4
2
1
0
0
10
20
30
40
50
60
70
Days

FIG. 2A



Karpas-299
Untreated
SGN-CD30C 0.5 mg/kg
Tumor Volume (mm3)
1500
1000
500
0
0
20
40
60
80
Days

FIG. 2B



Karpas-299
Untreated
BV 0.3 mg/kg
Tumor Volume (mm3)
1500
1000
500
0
0
20
40
60
80
Days

FIG. 2C




Karpas-299
Untreated
BV 0.3 mg/kg + SGN-CD30C 0.5 mg/kg
Tumor Volume (mm3)
1500
1000
500
0
0
20
40
60
80
Days

FIG. 2D


Karpas-299
Survival Based on Tumor Quadrupling
Percent Survival (Total % of mice)
100
80
60
40
20
0
0
20
40
60
80
Days
Untreated
BV 0.3 mg/kg
SGN-CD30C 0.5 mg/kg
BV 0.3 mg/kg + SGN-CD30C 0.5 mg/kg




FIG. 3A

FIG. 3B

FIG. 3C